Kronos Bio LLC

Kronos Bio LLC ROA

Delisted

The Return on Assets (ROA) of Kronos Bio LLC (KRON) as of Nov 2, 2026 is -69.22 %. In the previous year, Return on Assets (ROA) was -52.83 % — a change of 31.02% (lower).

ROA

-69.22 %

YoY

31.02%

Last updated:

In 2024, Kronos Bio LLC's return on assets (ROA) was -69.22 %, a 31.02% increase from the -52.83 % ROA in the previous year.

The Kronos Bio LLC ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-53.28 USD
Jan 1, 2019
-15.01 USD
Jan 1, 2020
-12.52 USD
Jan 1, 2021
-38.09 USD
Jan 1, 2022
-43.84 USD
Jan 1, 2023
-52.83 USD
Jan 1, 2024
-69.22 USD
The Kronos Bio LLC ROA history
YEARROAYoY
-69.22 %+31.02%
-52.83 %+20.51%
-43.84 %+15.10%
-38.09 %+204.26%
-12.52 %-16.63%
-15.01 %-71.82%
-53.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kronos Bio LLC Stock analysis

What does Kronos Bio LLC do? Kronos Bio Inc is a biotech company founded in 2017 by an experienced team, specialized in developing new therapeutics for cancer treatment. The company is based in Cambridge, Massachusetts and collaborates closely with leading scientific institutions. Kronos Bio Inc's business model focuses on identifying and researching new targets to develop drugs for the treatment of cancer and other diseases. The company utilizes artificial intelligence and machine learning to identify molecular mechanisms, enabling better prediction of the effectiveness of new drugs. Kronos Bio Inc is divided into different divisions, each focusing on specific therapeutic approaches. The "Transcription Regulation" division explores the control of gene expression in tumor cells and seeks potential points of intervention. The "Epigenetics" division, on the other hand, investigates how cells modify their DNA and the role this plays in the development of cancer. Another division focuses on blocking specific enzyme activities that are considered essential factors for the growth of tumor cells. Currently, Kronos Bio Inc does not offer concrete products as it is still in the development phase. However, the company has already established a number of collaborations with other companies and scientific institutions to research and further develop new drug candidates. One of the most significant partnerships is with the pharmaceutical company Gilead Sciences, which has the option to license selected drug candidates from Kronos Bio Inc as part of the collaboration. Overall, Kronos Bio has quickly made a name for itself in the biotech industry with its innovative approach and ambitious plans to develop new drugs against cancer. The company has raised several million dollars in capital and has prominent investors such as Omega Funds and Vida Ventures on board. The goal of Kronos Bio is to develop new therapies that allow for improved survival rates and a higher quality of life for cancer patients. Kronos Bio LLC is one of the most popular companies on Eulerpool.

ROA Details

Understanding Kronos Bio LLC's Return on Assets (ROA)

Kronos Bio LLC's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Kronos Bio LLC's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Kronos Bio LLC's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Kronos Bio LLC’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Kronos Bio LLC stock

Return on Assets (ROA) of Kronos Bio LLC is -69.22 % in 2024.

Return on Assets (ROA) of Kronos Bio LLC changed from -52.83 % to -69.22 %, representing a 31.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Kronos Bio LLC since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Kronos Bio LLC with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Kronos Bio LLC

All Key Metrics — Kronos Bio LLC